Send us a text

Dr. Peter Ordentlich, Ph.D. is Chief Scientific Officer and Founder, Syndax Pharmaceuticals ( https://syndax.com/team/peter-ordentlich-ph-d/ ), a company with a mission to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients, by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.

Dr. Ordentlich co-founded the Company in October 2005 and has served as Chief Scientific Officer since September 2016.

Dr. Ordentlich previously served as Syndax’s Chief Technical Officer, Vice President, Translational Medicine, Executive Director, Translational Science, and Director, Scientific Affairs and Strategic Alliances.

Prior to founding the company, Dr. Ordentlich was a scientist at the Salk Institute for Biological Studies, a biological research non-profit organization. He also spent five years as a research scientist at X-Ceptor Therapeutics, Inc., a drug discovery company, which was acquired by Exelixis, Inc.

Dr. Ordentlich received a B.A. in Biochemistry and a Ph.D. in Immunology from the University of Pennsylvania.

#PeterOrdentlich #SyndaxPharmaceuticals #Oncology #Cancer #Menin #KMT2Ar #AcuteLeukemias #NPM1m #AcuteMyeloidLeukemia #Revuforj #Niktimvo #Axatilimab #Revumenib #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #Research

Support the show